To study the role of targeting PHD2 in platelet aggregation, we used three PHD2 inhibitors, Dap, Rox, and Vad, which have been clinically approved for treating symptomatic anemia in chronic kidney disease patients32, 33, 34. This evidence concerns the gene EGLN1 and anemia (phenotype).